Skip to main content
. 2022 Sep 14;14(18):4464. doi: 10.3390/cancers14184464

Figure 4.

Figure 4

IFNγ and IL-17 expression in S-specific CD4 T-cells. Paired backgrounds from technical controls were removed from the data. (A–C) Percentage of IFNγ-CD4 T-cells specific for the S protein in healthy donors and oncologic patients. (D–F) Percentage of IL-17-CD4 T-cells specific for the S protein in healthy donors and oncologic patients. (A,B,D,E) Statistical significance was evaluated with the Kruskal–Wallis test, followed by Dunn´s pair-wise comparisons. (G) Percentage of CD4 T-cells expressing IL-17 and IFNγ in H-V donors that completed the vaccine regime before sample collection in the indicated timelines. (C,F,G) Significance was tested with the Mann–Whitney U-test. H-N/N—non-vaccinated, non-COVID-19 donors; H-CoV—healthy donors with previous COVID-19 infection; H-V—vaccinated healthy donor; H-CoV-V—vaccinated healthy donor with previous COVID-19; O-CoV—oncologic patient with previous COVID-19; O-V—vaccinated oncologic patients; O-CoV-V—vaccinated oncologic patients with previous COVID-19; ** and **** indicate very significant (p < 0.01) and very highly significant (p < 0.0001) differences, respectively.